N/A
N=18
Dexcom G6 for Total Pancreatectomy With Islet Autotransplantation (TPIAT) Patients
Diabetes
Bottom Line
View on ClinicalTrials.gov: NCT05607576 ↗Enrolled (actual)
18
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Dexcom G6 Accuracy Post Radiation Exposure by Clark Error Analysis (Zone A and B %) — 806; 1226; 704; 1715 Matched blood glucose readings — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Uncovered CGM during radiologic procedures (Other)
- Age
- Pediatric, Adult · 11+ yrs
- Sex
- All
- Sponsor
- Deborah Elder
- Primary completion
- Oct 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Dexcom G6 Accuracy Post Radiation Exposure by Clark Error Analysis (Zone A and B %) |
806; 1226; 704; 1715; 1020; 606 | <0.05 sig |
| PRIMARY Post Radiation Dexcom G6 Transmitter Functional Duration by Clark Error Analysis (Zone A and B %) |
2065; 446; 226; 1173; 128; 61 | <0.05 sig |
Summary
A single-center prospective trial on the effects of standard of care radiation exposure on the Dexcom G6 continuous glucose monitoring (CGM) device.
Eligibility Criteria
Inclusion Criteria
- Planned TPIAT at CCHMC
- Staying in-patient at CCHMC post TPIAT
- Planned to receive a Dexcom G6 CGM
Exclusion Criteria
- Hemo- or peritoneal dialysis
Data sourced from ClinicalTrials.gov (NCT05607576). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.